KROS250117C17500
- 1.20
- -0.30-20.00%
Keros Therapeutics Newsroom
Keros Therapeutics Is Maintained at Buy by Truist Securities
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential
Keros Therapeutics Analyst Ratings
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63
Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63
Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40
Keros Therapeutics Cut to Neutral From Buy by Guggenheim
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
Guggenheim Downgrades Keros Therapeutics(KROS.US) to Hold Rating
Keros Therapeutics Is Maintained at Sector Outperform by Scotiabank
Keros Therapeutics Price Target Cut to $44.00/Share From $77.00 by Scotiabank
Jefferies Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $44
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $47 to $84
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Lowers Price Target to $47
Keros Therapeutics Cut to Market Perform From Outperform by William Blair